Analgesic-antitumor peptide induces apoptosis and inhibits the proliferation of SW480 human colon cancer cells

Oncology Letters

Volumn 5, Issue 2, 2013, Pages 483-488

  Gu, Yu ^a   Liu, Shen Lin ^b   Ju, Wen Zheng ^b   Li, Chang Yin ^b   Cao, Peng ^c  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c Jiangsu Province Institute of Traditional Chinese Medicine   (China)

Author keywords

Analgesic antitumor peptide; Apoptosis; Cell cycle; Colorectal cancer; Proliferation

Indexed keywords

ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P27; RECOMBINANT ANALGESIC ANTITUMOR PEPTIDE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

EID: 84871547634     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.1049     Document Type: Article

References (41)

1. Center MM, Jemal A, Smith RA and Ward E: Worldwide variations in colorectal cancer. CA Cancer J Clin 59: 366-378, 2009.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
3. Weekes J, Lam AK, Sebesan S and Ho YH: Irinotecan therapy and molecular targets in colorectal cancer: a systemic review. World J Gastroenterol 15: 3597-3602, 2009.
4. Zhao Y, Cai X, Ye T, et al: Analgesic-antitumor peptide inhibits proliferation and migration of SHG-44 human malignant glioma cells. J Cell Biochem 112: 2424-2434, 2011.
5. Cao P, Yu J, Lu W, et al: Expression and purification of an antitumor-analgesic peptide from the venom of Mesobuthus martensii Karsch by small ubiquitin-related modifier fusion in Escherichia coli. Biotechnol Prog 26: 1240-1244, 2010.
6. Guo Y, Srinivasula SM, Druilhe A, Fernandes-Alnemri T and Alnemri ES: Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J Biol Chem 277: 13430-13437, 2002.
7. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634, 2008.
8. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765, 2008.
9. Deorukhkar A, Krishnan S, Sethi G and Aggarwal BB: Back to basics: how natural products can provide the basis for new therapeutics. Expert Opin Investig Drugs 16: 1753-1773, 2007.
10. Newman DJ and Cragg GM: Natural products as sources of new drugs over the last 25 years. J Nat Prod 70: 461-477, 2007.
11. du Plessis LH, Elgar D and du Plessis JL: Southern African scorpion toxins: an overview. Toxicon 51: 1-9, 2008.
12. Rodriguez de la Vega RC and Possani LD: Overview of scorpion toxins specific for Na+ channels and related peptides: biodiversity, structure-function relationships and evolution. Toxicon 46: 831-844, 2005.
13. Fan S, Sun Z, Jiang D, et al: BmKCT toxin inhibits glioma proliferation and tumor metastasis. Cancer Lett 291: 158-166, 2010.
14. Das Gupta S, Debnath A, Saha A, et al: Indian black scorpion (Heterometrus bengalensis Koch) venom induced antiproliferative and apoptogenic activity against human leukemic cell lines U937 and K562. Leukemia 31: 817-825, 2007.
15. Gao R, Zhang Y and Gopalakrishnakone P: Purification and N-terminal sequence of a serine proteinase-like protein (BMK-CBP) from the venom of the Chinese scorpion (Buthus martensii Karsch). Toxicon 52: 348-353, 2008.
16. Chaudhry MA: Base excision repair of ionizing radiation-induced DNA damage in G1 and G2 cell cycle phases. Cancer Cell Int 7: 15, 2007.
17. Sitko JC, Yeh B, Kim M, et al: SOCS3 regulates p21 expression and cell cycle arrest in response to DNA damage. Cell Signal 20: 2221-2230, 2008.
18. Narbonne-Reveau K and Lilly M: The Cyclin-dependent kinase inhibitor Dacapo promotes genomic stability during premeiotic S phase. Mol Biol Cell 20: 1960-1969, 2009.
19. Liu S and Yamauchi H: p27-Associated G1 arrest induced by hinokitiol in human malignant melanoma cells is mediated via down-regulation of pRb, Skp2 ubiquitin ligase, and impairment of Cdk2 function. Cancer Lett 286: 240-249, 2009.
20. Connor MK, Kotchetkov R, Cariou S, et al: CRM1/Ran-mediated nuclear export of p27(Kip1) involves a nuclear export signal and links p27 export and proteolysis. Mol Biol Cell 14: 201-213, 2003.
21. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S and Arteaga CL: Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62: 4132-4141, 2002.
22. Kerkhoff E, Simpson JC, Leberfinger CB, et al: The Spir actin organizers are involved in vesicle transport processes. Curr Biol 11: 1963-1968, 2001.
23. Jones SM and Kazlauskas A: Growth-factor-dependent mitogenesis requires two distinct phases of signalling. Nat Cell Biol 3: 165-172, 2001.
24. Liang J, Zubovitz J, Petrocelli T, et al: PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 8: 1153-1160, 2002.
25. Liang J and Slingerland JM: Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2: 339-345, 2003.
26. Petros AM, Olejniczak ET and Fesik SW: Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 1644: 83-94, 2004.
27. Chowdhury I, Tharakan B and Bhat GK: Caspases-an update. Comp Biochem Physiol B Biochem Mol Biol 151: 10-27, 2008.
28. D'Amelio M, Tino E and Cecconi F: The apoptosome: emerging insights and new potential targets for drug design. Pharm Res 25: 740-751, 2008.
29. Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
30. Di Cristofano A and Pandolfi PP: The multiple roles of PTEN in tumor suppression. Cell 100: 387-390, 2000.
31. Laurent-Puig P, Cayre A, Manceau G, et al: Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27: 5924-5930, 2009.
32. Loupakis F, Pollina L, Stasi I, et al: PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27: 2622-2629, 2009.
33. Frattini M, Saletti P, Romagnani E, et al: PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97: 1139-1145, 2007.
34. Vyas S, Juin P, Hancock D, et al: Differentiation-dependent sensitivity to apoptogenic factors in PC12 cells. J Biol Chem 279: 30983-30993, 2004.
35. Majewski N, Nogueira V, Robey RB and Hay N: Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Mol Cell Biol 24: 730-740, 2004.
36. Engelman JA, Luo J and Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606-619, 2006.
37. Carnero A: The PKB/AKT pathway in cancer. Curr Pharm Des 16: 34-44, 2010.
38. Song G, Ouyang G and Bao S: The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9: 59-71, 2005.
39. Liu J, Yin S, Reddy N, Spencer C and Sheng S: Bax mediates the apoptosis-sensitizing effect of maspin. Cancer Res 64: 1703-1711, 2004.
40. Maianski NA, Geissler J, Srinivasula SM, Alnemri ES, Roos D and Kuijpers TW: Functional characterization of mitochondria in neutrophils: a role restricted to apoptosis. Cell Death Differ 11: 143-153, 2004.
41. Kang MH and Reynolds CP: Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15: 1126-1132, 2009.